Moneycontrol PRO
HomeNewsBusinessWockhardt, Serum Institute to invest and share profit equally from new UK jab plant: Habil Khorakiwala

Wockhardt, Serum Institute to invest and share profit equally from new UK jab plant: Habil Khorakiwala

Wockhardt chairman Habil Khorakiwala declined comment on reports that Serum is looking to buy a stake in Wockhardt

March 21, 2022 / 13:07 IST
Wockhardt Chairman Habil Khorakiwala

A unit of Indian drugmaker Wockhardt has partnered a subsidiary of Serum Institute of India (SII) to set up a vaccine facility in Wrexham, North Wales where both parties are ''nearly equally investing'' and will be having nearly equal profit sharing.

Wockhardt chairman Habil Khorakiwala told CNBC TV-18 that the facility in the UK will take ''a year-plus'' to operationalise and declined comment on reports that Serum is looking to buy a stake in Wockhardt.

''A range of vaccines from Serum, in addition to COVID-19 vaccines, will be manufactured via our UK fill and finish facility,'' Khorakiwala said in the exclusive interview.

Also Read: Wockhardt unit partners with SII subsidiary to set up vaccine manufacturing plant in UK

The collaboration between Wockhardt UK and Serum Life Sciences UK will help create employment and the facility will deliver 150 million doses of multiple vaccines, according to a statement.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

''We are establishing ourselves as a principal manufacturer of fill and finish vaccines - not just during the pandemic – but subsequently in the endemic situation also, as far as COVID-19 is concerned,'' said Khorakiwala.

Wockhardt UK has manufactured COVID-19 vaccine in collaboration with the UK government and AstraZeneca. Its tie-up with Serum comes as an addition to the earlier arrangement.

On March 21 - a day after the deal was announced - shares of Wockhardt rallied as much as 12 percent. At 1:03 pm, shares traded 11.98 percent higher at Rs 327.25 on the BSE.

 

Moneycontrol News
first published: Mar 21, 2022 01:31 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347